المؤلفون: Martino M; Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Grande Ospedale Metropolitano 'Bianchi-Melacrino-Morelli', Reggio Calabria, Italy., Gamberi B; Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Reggio Emilia, Italy., Antonioli E; Hematology Department, Careggi Hospital, Florence, Italy., Aquino S; Hematology and Hematopoietic Stem Cell Transplantation Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Della Pepa R; Hematology Unit, Department of Clinical Medicine and Surgery, University of Naples 'Federico II', Naples, Italy., Malerba L; Haematology and Haematopoietic Stem Cell Transplant Center, AST, Pesaro Urbino, Pesaro, Italy., Mangiacavalli S; Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Pezzatti S; Department of Haematology, San Gerardo Hospital, Monza, MB, Italy., Bringhen S; SSD Clinical trial in oncoematologia e mieloma multiplo, Dipartimento di Oncologia, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy., Zamagni E; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy.; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.

المصدر: Expert review of hematology [Expert Rev Hematol] 2024 Jul; Vol. 17 (7), pp. 375-390. Date of Electronic Publication: 2024 May 21.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101485942 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1747-4094 (Electronic) Linking ISSN: 17474094 NLM ISO Abbreviation: Expert Rev Hematol Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Bispecific*/therapeutic use , Immunotherapy, Adoptive*/methods , Immunotherapy, Adoptive*/adverse effects , Multiple Myeloma*/therapy , Multiple Myeloma*/immunology , B-Cell Maturation Antigen*/immunology , B-Cell Maturation Antigen*/antagonists & inhibitors, Humans ; Receptors, Chimeric Antigen/immunology ; Receptors, Chimeric Antigen/therapeutic use ; Immunotherapy/methods ; T-Lymphocytes/immunology

المؤلفون: Eslami M; Department of Immunobiology, University of Lausanne, Epalinges 1066, Switzerland., Schuepbach-Mallepell S; Department of Immunobiology, University of Lausanne, Epalinges 1066, Switzerland., Diana D; Department of Immunobiology, University of Lausanne, Epalinges 1066, Switzerland., Willen L; Department of Immunobiology, University of Lausanne, Epalinges 1066, Switzerland., Kowalczyk-Quintas C; Department of Immunobiology, University of Lausanne, Epalinges 1066, Switzerland., Desponds C; Department of Immunobiology, University of Lausanne, Epalinges 1066, Switzerland., Peter B; Department of Immunobiology, University of Lausanne, Epalinges 1066, Switzerland., Vigolo M; Department of Immunobiology, University of Lausanne, Epalinges 1066, Switzerland., Renevey F; Department of Immunobiology, University of Lausanne, Epalinges 1066, Switzerland., Donzé O; AdipoGen Life Sciences, Epalinges 1066, Switzerland., Luther SA; Department of Immunobiology, University of Lausanne, Epalinges 1066, Switzerland., Yalkinoglu Ö; Clinical Pharmacology, Global Early Development, The Healthcare Business of Merck KGaA, Darmstadt 64293, Germany., Alouche N; Department of Immunobiology, University of Lausanne, Epalinges 1066, Switzerland., Schneider P; Department of Immunobiology, University of Lausanne, Epalinges 1066, Switzerland.

المصدر: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2024 Jul 16; Vol. 121 (29), pp. e2404309121. Date of Electronic Publication: 2024 Jul 11.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: National Academy of Sciences Country of Publication: United States NLM ID: 7505876 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1091-6490 (Electronic) Linking ISSN: 00278424 NLM ISO Abbreviation: Proc Natl Acad Sci U S A Subsets: MEDLINE

مواضيع طبية MeSH: B-Cell Activating Factor*/immunology , B-Cell Activating Factor*/metabolism , B-Cell Activating Factor*/genetics , Tumor Necrosis Factor Ligand Superfamily Member 13*/metabolism , Tumor Necrosis Factor Ligand Superfamily Member 13*/immunology , Tumor Necrosis Factor Ligand Superfamily Member 13*/genetics , B-Cell Maturation Antigen*/immunology , B-Cell Maturation Antigen*/metabolism , Transmembrane Activator and CAML Interactor Protein*/metabolism , Transmembrane Activator and CAML Interactor Protein*/genetics , Transmembrane Activator and CAML Interactor Protein*/immunology , Interleukin-6*/metabolism , Interleukin-6*/immunology , B-Cell Activation Factor Receptor*/metabolism , B-Cell Activation Factor Receptor*/immunology , B-Cell Activation Factor Receptor*/genetics, Animals ; Mice ; Plasma Cells/immunology ; Plasma Cells/metabolism ; Mice, Knockout ; Antibody-Producing Cells/immunology ; Antibody-Producing Cells/metabolism ; Mice, Inbred C57BL

المؤلفون: Ledergor G; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA., Fan Z; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA., Wu K; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, WA., McCarthy E; Institute for Human Genetics, University of California, San Francisco, San Francisco, CA., Hyrenius-Wittsten A; Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA.; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden., Starzinski A; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA., Chang H; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA., Bridge M; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA., Kwek S; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA., Cheung A; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA., Bylsma S; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA., Hansen E; Department of Orthopedic Surgery, University of California, San Francisco, San Francisco, CA., Wolf J; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA., Wong S; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA., Shah N; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA., Roybal KT; Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA.; Parker Institute for Cancer Immunotherapy, San Francisco, CA., Martin T; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA., Ye CJ; Institute for Human Genetics, University of California, San Francisco, San Francisco, CA.; Parker Institute for Cancer Immunotherapy, San Francisco, CA., Fong L; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, WA.; Parker Institute for Cancer Immunotherapy, San Francisco, CA.

المصدر: Blood advances [Blood Adv] 2024 Jul 09; Vol. 8 (13), pp. 3562-3575.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/therapy , Multiple Myeloma*/immunology , B-Cell Maturation Antigen*/metabolism , B-Cell Maturation Antigen*/immunology , Immunotherapy, Adoptive*/methods , Receptors, Chimeric Antigen*/immunology , Receptors, Chimeric Antigen*/metabolism , CD4-Positive T-Lymphocytes*/immunology , CD4-Positive T-Lymphocytes*/metabolism, Humans ; Recurrence ; Male ; Female ; T-Cell Exhaustion

المؤلفون: Nagarajan C; Department of Haematology, Singapore General Hospital and SingHealth DUKE NUS Blood Cancer Center, Singapore, Singapore. Electronic address: chandramouli.nagarajan@Singhealth.com.sg., Eu Jo MW; Department of Radiology, Singapore General Hospital, Singapore., Martin TG 3rd; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, USA.

المصدر: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Jul; Vol. 24 (7), pp. 488-490. Date of Electronic Publication: 2024 Mar 16.

نوع المنشور: Journal Article; Case Reports; Letter

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/drug therapy , Antibodies, Bispecific*/therapeutic use , Antibodies, Bispecific*/pharmacology , B-Cell Maturation Antigen*/antagonists & inhibitors , B-Cell Maturation Antigen*/immunology, Humans ; Male ; Middle Aged ; Female

المؤلفون: Moles MW; Translational Tumorimmunology, Max Delbrück Center, Berlin, Germany., Erdlei H; Translational Tumorimmunology, Max Delbrück Center, Berlin, Germany., Menzel L; Translational Tumorimmunology, Max Delbrück Center, Berlin, Germany., Massaro M; Microenvironmental Regulation in Autoimmunity and Cancer, Max Delbrück Center, Berlin, Germany., Fiori A; Translational Tumorimmunology, Max Delbrück Center, Berlin, Germany., Bunse M; Microenvironmental Regulation in Autoimmunity and Cancer, Max Delbrück Center, Berlin, Germany., Schrimpf M; Translational Tumorimmunology, Max Delbrück Center, Berlin, Germany., Gerlach K; Translational Tumorimmunology, Max Delbrück Center, Berlin, Germany., Gudipati V; Center for Pathophysiology, Infectiology and Immunology, Institute for Hygiene and Applied Immunology, Medical University of Vienna, Vienna, Austria., Reiser J; Fate Therapeutics, San Diego, CA, United States., Mathavan K; Fate Therapeutics, San Diego, CA, United States., Goodrich JP; Fate Therapeutics, San Diego, CA, United States., Huppa JB; Center for Pathophysiology, Infectiology and Immunology, Institute for Hygiene and Applied Immunology, Medical University of Vienna, Vienna, Austria., Krönke J; Department of Hematology, Oncology and Tumorimmunology, Charité-University Medicine Berlin, Berlin, Germany., Valamehr B; Fate Therapeutics, San Diego, CA, United States., Höpken UE; Microenvironmental Regulation in Autoimmunity and Cancer, Max Delbrück Center, Berlin, Germany., Rehm A; Translational Tumorimmunology, Max Delbrück Center, Berlin, Germany.

المصدر: Frontiers in immunology [Front Immunol] 2024 Jun 24; Vol. 15, pp. 1383136. Date of Electronic Publication: 2024 Jun 24 (Print Publication: 2024).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/immunology , Multiple Myeloma*/therapy , Receptors, CXCR4*/metabolism , Receptors, CXCR4*/genetics , B-Cell Maturation Antigen*/immunology , B-Cell Maturation Antigen*/metabolism , B-Cell Maturation Antigen*/genetics , Killer Cells, Natural*/immunology , Killer Cells, Natural*/metabolism , Receptors, Chimeric Antigen*/immunology , Receptors, Chimeric Antigen*/genetics , Receptors, Chimeric Antigen*/metabolism , Immunotherapy, Adoptive*/methods , Chemokine CXCL12*/metabolism, Humans ; Cell Line, Tumor ; Cytotoxicity, Immunologic

المؤلفون: Tryggestad SS; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway., Roseth IA; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway., Aass KR; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway., Ørning NEH; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway., Mjelle R; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.; Department of Pathology, St. Olavs University Hospital, Trondheim, Norway., Hella H; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway., Standal T; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.; Department of Hematology, St. Olavs University Hospital, Trondheim, Norway.

المصدر: Frontiers in immunology [Front Immunol] 2024 Jun 07; Vol. 15, pp. 1393906. Date of Electronic Publication: 2024 Jun 07 (Print Publication: 2024).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/genetics , Multiple Myeloma*/immunology , Multiple Myeloma*/metabolism , Signal Transduction* , B-Cell Maturation Antigen*/genetics , B-Cell Maturation Antigen*/metabolism , B-Cell Maturation Antigen*/immunology , Toll-Like Receptors*/metabolism , Proto-Oncogene Proteins c-myc*/genetics , Proto-Oncogene Proteins c-myc*/metabolism , Gene Expression Regulation, Neoplastic*, Humans ; Cell Line, Tumor ; Proto-Oncogene Proteins c-bcl-2/genetics ; Proto-Oncogene Proteins c-bcl-2/metabolism ; Bortezomib/pharmacology ; Bortezomib/therapeutic use ; Male

المؤلفون: Moore DC; Department of Pharmacy, Atrium Health, Levine Cancer Institute, Charlotte, NC, USA., Granger K; Hollings Cancer Center, Department of Pharmacy, The Medical University of South Carolina, Charleston, SC, USA., Hill H; Department of Pharmacy, Atrium Health, Levine Cancer Institute, Charlotte, NC, USA., Karabinos A; Department of Pharmacy, Atrium Health, Levine Cancer Institute, Charlotte, NC, USA., Davis JA; Hollings Cancer Center, Department of Pharmacy, The Medical University of South Carolina, Charleston, SC, USA.

المصدر: Expert review of hematology [Expert Rev Hematol] 2024 Jun; Vol. 17 (6), pp. 197-200. Date of Electronic Publication: 2024 May 11.

نوع المنشور: Editorial

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101485942 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1747-4094 (Electronic) Linking ISSN: 17474094 NLM ISO Abbreviation: Expert Rev Hematol Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/drug therapy , Multiple Myeloma*/therapy , Antibodies, Bispecific*/therapeutic use , B-Cell Maturation Antigen*/antagonists & inhibitors , B-Cell Maturation Antigen*/metabolism, Humans ; Antibodies, Monoclonal, Humanized/therapeutic use ; Recurrence ; Drug Resistance, Neoplasm

المؤلفون: Oliver-Caldes A; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.; Hospital Universitari Son Espases, IDISBA, Palma de Mallorca, Spain., Español-Rego M; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Zabaleta A; Clínica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, CIBER-ONC Number CB16/12/00369, Pamplona, Spain., González-Calle V; Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Salamanca, Spain., Navarro-Velázquez S; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Inogés S; Clínica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, CIBER-ONC Number CB16/12/00369, Pamplona, Spain., de Cerio AL; Clínica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, CIBER-ONC Number CB16/12/00369, Pamplona, Spain., Cabañas V; Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, University of Murcia, Murcia, Spain., López-Muñoz N; Hospital Universitario 12 de Octubre, Complutense University, i+12, CNIO, Madrid, Spain., Rodríguez-Otero P; Clínica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, CIBER-ONC Number CB16/12/00369, Pamplona, Spain., Reguera JL; Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC), University of Sevilla, Sevilla, Spain., Moreno DF; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Martínez-Cibrian N; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., López-Corral L; Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Salamanca, Spain., Pérez-Amill L; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Martin-Antonio B; Department of Experimental Hematology, Instituto de Investigación Sanitaria- Fundación Jiménez Díaz, University Autonomous of Madrid, Madrid, Spain., Rosiñol L; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Cid J; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Tovar N; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Sáez-Peñataro J; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., López-Parra M; Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Salamanca, Spain., Olesti E; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Guillén E; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Varea S; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Rodríguez-Lobato LG; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Battram AM; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., González MS; Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain., Sánchez-Salinas A; Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, University of Murcia, Murcia, Spain., González-Navarro A; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Ortiz-Maldonado V; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Delgado J; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Prósper F; Clínica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, CIBER-ONC Number CB16/12/00369, Pamplona, Spain., Juan M; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Martínez-López J; Hospital Universitario 12 de Octubre, Complutense University, i+12, CNIO, Madrid, Spain., Moraleda JM; Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, University of Murcia, Murcia, Spain., Mateos MV; Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Salamanca, Spain., Urbano-Ispizua Á; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Paiva B; Clínica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, CIBER-ONC Number CB16/12/00369, Pamplona, Spain., Pascal M; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Fernández de Larrea C; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 May 15; Vol. 30 (10), pp. 2085-2096.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/therapy , Multiple Myeloma*/immunology , Multiple Myeloma*/drug therapy , B-Cell Maturation Antigen*/immunology , B-Cell Maturation Antigen*/antagonists & inhibitors , Immunotherapy, Adoptive*/adverse effects , Immunotherapy, Adoptive*/methods, Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Biomarkers, Tumor ; Receptors, Chimeric Antigen/immunology ; Treatment Outcome

المؤلفون: Reyes KR; School of Medicine, University of California San Francisco, San Francisco, CA., Liu YC; Department of Statistical Science, Duke University, Durham, NC., Huang CY; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA., Banerjee R; Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA.; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA., Martin T; Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA., Wong SW; Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA., Wolf JL; Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA., Arora S; Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA., Shah N; Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA., Chari A; Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA., Chung A; Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA.

المصدر: Blood advances [Blood Adv] 2024 May 14; Vol. 8 (9), pp. 2207-2216.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: B-Cell Maturation Antigen*/antagonists & inhibitors , B-Cell Maturation Antigen*/immunology , Multiple Myeloma*/therapy , Multiple Myeloma*/mortality , Multiple Myeloma*/immunology , Salvage Therapy*/methods , Immunotherapy, Adoptive*/methods, Humans ; Male ; Female ; Middle Aged ; Aged ; Retrospective Studies ; Retreatment ; Adult ; Treatment Outcome ; Recurrence ; Receptors, Chimeric Antigen/therapeutic use

المؤلفون: Jagannath S; Multiple Myeloma Division, Tisch Cancer Institute, Mount Sinai Medical Center New York, New York, NY, USA., Jackson CC; Janssen Research & Development, Raritan, NJ, USA., Schecter JM; Janssen Research & Development, Raritan, NJ, USA., Lendvai N; Janssen Research & Development, Raritan, NJ, USA., Sun H; Janssen Research & Development, Raritan, NJ, USA., Akram M; Legend Biotech USA Inc, Somerset, NJ, USA., Patel N; Legend Biotech USA Inc, Somerset, NJ, USA., Martin TG; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.

المصدر: Expert opinion on biological therapy [Expert Opin Biol Ther] 2024 May; Vol. 24 (5), pp. 339-350. Date of Electronic Publication: 2024 May 13.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101125414 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-7682 (Electronic) Linking ISSN: 14712598 NLM ISO Abbreviation: Expert Opin Biol Ther Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/therapy , Multiple Myeloma*/immunology , Multiple Myeloma*/mortality , Immunotherapy, Adoptive*/adverse effects , B-Cell Maturation Antigen*/immunology, Humans ; Biological Products/therapeutic use ; Biological Products/adverse effects ; Receptors, Chimeric Antigen/immunology